Jianan Jin

Jianan Jin

Auto-generated profile, based on publicly available information

Jianan Jin

Graduate School, Zhejiang Chinese Medical University, People's Republic of China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2025 in Medicine
Verified
Journal Article
Open access
SZShiqi Mmed Zhang
Shiqi Mmed Zhang
JJJianan Mmed Jin
Jianan Mmed Jin
QZQi Zheng
Qi Zheng
WZWang Zhenyu
Wang Zhenyu
The occurrence and progression of cancer is a significant focus of research worldwide, often accompanied by a prolonged disease course. Concurrently, researchers have identified that social determinants of health (SDOH) (employment status, family income and poverty ratio, food security, education level, access to healthcare services, health insurance, housing conditions, and marital status) are associated with the progression of many chronic diseases. However, there is a paucity of research examining the influence of SDOH on cancer incidence risk and the survival of cancer survivors. The aim of this study was to utilize SDOH as a primary predictive factor, integrated with machine learning models, to forecast both cancer risk and prognostic survival. This research is grounded in the SDOH data derived from the National Health and Nutrition Examination Survey dataset spanning 1999 to 2018. It employs methodologies including adaptive boosting, gradient boosting machine (GradientBoosting), random forest (RF), extreme gradient boosting, light gradient boosting machine, support vector machine, and logistic regression to develop models for predicting cancer risk and prognostic survival. The hyperparameters of these models—specifically, the number of estimators (100–200), maximum tree depth (10), learning rate (0.01–0.2), and regularization parameters—were optimized through grid search and cross-validation, followed by performance evaluation. Shapley Additive exPlanations plots were generated to visualize the influence of each feature. RF was the best model for predicting cancer risk (area under the curve: 0.92, accuracy: 0.84). Age, non-Hispanic White, sex, and housing status were the 4 most important characteristics of the RF model. Age, gender, employment status, and household income/poverty ratio were the 4 most important features in the gradient boosting machine model. The predictive models developed in this study exhibited strong performance in estimating cancer incidence risk and survival time, identifying several factors that significantly influence both cancer incidence risk and survival, thereby providing new evidence for cancer management. Despite the promising findings, this study acknowledges certain limitations, including the omission of risk factors in the cancer survivor survival model and potential biases inherent in the National Health and Nutrition Examination Survey dataset. Future research is warranted to further validate the model using external datasets.

1 January 2024 in Cancer Control
Verified
Journal Article
Open access
JJJianan Jin
Jianan Jin
HMHaibo Mou
Haibo Mou
YZYibin Zhou
Yibin Zhou
SZShiqi Zhang
Shiqi Zhang
Background: Immune therapy, especially involving PD-1/PD-L1 inhibitors, has shown promise as a therapeutic option for cholangiocarcinoma. However, limited studies have evaluated survival outcomes in cholangiocarcinoma patients treated with immune therapy. This study aims to develop a predictive model to evaluate the survival benefits of immune therapy in patients with cholangiocarcinoma. Methods: This retrospective analysis included 120 cholangiocarcinoma patients from Shulan (Hangzhou) Hospital. Univariate and multivariate Cox regression analyses were conducted to identify factors associated with survival following immune therapy. A predictive model was constructed and validated using calibration curves (CC), decision curve analysis (DCA), concordance index (C-index), and receiver operating characteristic (ROC) curves. Results: Cox regression analysis identified several factors as potential predictors of survival post-immune therapy in cholangiocarcinoma: treatment cycle (<6 vs ≥ 6 months, 95% CI: 0.119-0.586, P = 0.001), neutrophil-to-lymphocyte ratio (NLR <3.08 vs ≥ 3.08, 95% CI: 1.864-9.624, P = 0.001), carcinoembryonic antigen (CEA <4.13 vs ≥ 4.13, 95% CI: 1.175-5.321, P = 0.017), and presence of bone metastasis (95% CI: 1.306-6.848, P = 0.010). The nomogram model achieved good predictive accuracy with a C-index of 0.811. CC indicated strong concordance between the predicted and observed outcomes. Multi-timepoint ROC curves at 1, 2, and 3 years validated the model’s performance (1-year AUC: 0.906, 2-year AUC: 0.832, 3-year AUC: 0.822). The multi-timepoint DCA curves also demonstrated a higher net benefit compared to extreme curves. Conclusion: The nomogram model, incorporating key risk factors for cholangiocarcinoma patients post-immune therapy, demonstrates robust predictive accuracy for survival outcomes, offering the potential for improved clinical decision-making.

2 February 2026 in PLOS ONE
Verified
Journal Article
Open access
ZWZhenyu Wang
Zhenyu Wang
JJJianan Jin
Jianan Jin
GWGuimei Wang
Guimei Wang
GZGuoqi Zhou
Guoqi Zhou
HJHanliang Jiang
Hanliang Jiang
Background: Proton pump inhibitors (PPIs), known for their potent acid-suppressing effects, are widely used in various clinical settings, including treatment and prevention. Understanding their adverse effects is crucial. This study, utilizing the FDA Adverse Event Reporting System (FAERS) database, comprehensively analyzes PPI-related adverse events to guide clinical medication practices. Methods: This study analyzed suspected adverse drug reactions (ADRs) related to specific PPI drugs using data from the FAERS database, covering Q1 2004 to Q4 2024. Multiple statistical methods, including ROR, PRR, IC025, and EBGM, were employed for evaluation, with ADRs defined according to System Organ Class (SOC) and Preferred Term (PT). A comparative analysis was conducted to assess potential differences in ADR profiles among different PPI drugs. Results: This study analyzed 176,680 cases of PPI-related adverse events, with a total of 632,468 adverse reaction reports recorded when PPIs were designated as the primary suspected drug (PS). PPIs showed significantly elevated risks in the renal/urinary and gastrointestinal systems, with other common adverse reactions including hypomagnesemia, hypocalcemia, and renal anemia. Most adverse reactions occurred either within the first 0–30 days of use or after prolonged exposure (>6 months), and elderly patients (≥65 years) were disproportionately affected. Conclusions: For high-risk populations using PPIs long-term (such as elderly patients or those with pre-existing renal impairment), continuous monitoring is essential to mitigate potential complications. Unnecessary use should be strictly avoided, and long-term medication should be minimized to ensure safety and appropriateness.